lansoprazole is an antiulcer drug owned by Dexcel Pharma. The drug contains lansoprazole as the active ingredient. It was first authorised for market use on 07 June, 2016. lansoprazole is available in the form of a delayed release orally disintegrating tablet suitable for oral consumption.
Lansoprazole generic is expected to be available after 21 April, 2036. This date is determined by the last patent 'Orally disintegrating compositions' held by the drug, which is due to expire on this date.
lansoprazole is used for the treatment of ulcers, gastroesophageal reflux disease (GERD), and Zollinger-Ellison Syndrome. The active ingredient, lansoprazole, functions by reducing the amount of acid your stomach makes, thus providing relief.
Lansoprazole has a total of 1 drug patent, none of which have expired. The last patent 'Orally disintegrating compositions' is set to expire on 21 April, 2036. Below is the detail of the patent: